Bioventus Inc (BVS) - Total Liabilities
Based on the latest financial reports, Bioventus Inc (BVS) has total liabilities worth $395.93 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Bioventus Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Bioventus Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Bioventus Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Bioventus Inc assets under control.
Bioventus Inc Competitors by Total Liabilities
The table below lists competitors of Bioventus Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mingyue Optical Lens Co.Ltd.
SHE:301101
|
China | CN¥231.16 Million |
|
Ningbo Dechang Electrical Machinery Made Co Ltd
SHG:605555
|
China | CN¥2.19 Billion |
|
Beijing CTJ Information Technology Co. Ltd.
SHE:301153
|
China | CN¥493.64 Million |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩8.60 Billion |
|
Standard Lithium Ltd
NYSE MKT:SLI
|
USA | $33.74 Million |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
Thailand | ฿3.28 Billion |
|
Neurones
PA:NRO
|
France | €284.16 Million |
|
Plazza AG
SW:PLAN
|
Switzerland | CHF555.12 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Bioventus Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BVS net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioventus Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioventus Inc (2014–2025)
The table below shows the annual total liabilities of Bioventus Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $455.11 Million | -16.09% |
| 2024-12-31 | $542.35 Million | -8.04% |
| 2023-12-31 | $589.79 Million | -38.59% |
| 2022-12-31 | $960.43 Million | +38.78% |
| 2021-12-31 | $692.07 Million | +97.56% |
| 2020-12-31 | $350.31 Million | +7.20% |
| 2019-12-31 | $326.79 Million | +9.86% |
| 2018-12-31 | $297.46 Million | +0.83% |
| 2015-12-31 | $295.01 Million | +16.64% |
| 2014-12-31 | $252.93 Million | -- |
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis… Read more